TrialPLoS medicine2017

Safety, pharmacokinetics, and immunological activities of multiple intravenous or subcutaneous doses of an anti-HIV monoclonal antibody, VRC01, administered to HIV-uninfected adults: Results of a phase 1 randomized trial.

Kenneth H Mayer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.